Amino acid differences in the deduced 5-lipoxygenase sequence of CAST atherosclerosis-resistance mice confer impaired activity when introduced into the human ortholog

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 6, 2003, Pages 1072-1076

  Kuhn, Hartmut ^a   Anton, Monika ^a   Gerth, Christa ^a   Habenicht, Andreas ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Atherogenesis; Eicosanoids; Inflammation; Leukotrienes; Mutation

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ICOSANOID; LEUKOTRIENE;

AMINO ACID SUBSTITUTION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BIOSYNTHESIS; BREEDING; CHROMOSOME 6; CONTROLLED STUDY; ENANTIOMER; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME SUBSTRATE; GENE CLUSTER; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; INFLAMMATION; MOUSE; MOUSE STRAIN; NONHUMAN; ORTHOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION;

AMINO ACID SUBSTITUTION; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; ARTERIOSCLEROSIS; CATALYSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, NATURAL; MICE; MICE, MUTANT STRAINS; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; RECOMBINANT PROTEINS; SPECIES SPECIFICITY; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 0037495055     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000074167.01184.48     Document Type: Article

References (22)

1. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 1987;237:1171-1176.
2. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294:1871-1875.
3. Spanbroek R, Gräbner R, Lötzer K, Hildner M, Urbach A, Rühling K, Moos MPW, Kaiser B, Cohnert TU, Wahlers T, Zieske A, Plenz G, Robenek H, Salbach P, Kühn H, Radmark O, Samuelsson B, Habenicht AJR. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A. 2003;100:1238-1243.
4. Mehrabian M, Allayee H, Wong J, Shih W, Wang XP, Shaposhnik Z, Funk CD, Lusis AJ. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res. 2002;91:120-126.
5. Funk CD, Chen XS, Johnson EN, Zhao L. Lipoxygenase genes and their targeted disruption. Prostaglandins Other Lip Med. 2002;68-69:303-312.
6. Mehrabian M, Wong J, Wang X, Jiang Z, Shih W, Fogelman A, Lusis AJ. Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ Res. 2001;89:125-130.
7. Schwarz K, Gerth C, Anton M, Kuhn H. Alterations in leukotriene synthase activity of the human 5-lipoxygenase by site-directed mutagenesis affecting its positional specificity. Biochemistry. 2000;39:14515-14521.
8. Denis D, Falgueyret JP, Riendeau D, Abramovitz M. Characterization of the activity of purified recombinant human 5-lipoxygenase in the absence and presence of leukocyte factors. J Biol Chem. 1991;266:5072-5079.
9. Aharony D, Stein RL. Kinetic mechanism of guinea pig neutrophil 5-lipoxygenase. J Biol Chem. 1986;261:11512-11519.
10. Shimizu T, Izumi T, Seyama Y, Tadokoro K, Radmark O, Samuelsson B. Characterization of leukotriene A4 synthase from murine mast cells: evidence for its identity to arachidonate 5-lipoxygenase. Proc Natl Acad Sci U S A. 1986;83:4175-4179.
11. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modification of low density lipoprotein that increases its atherogenicity. N Engl J Med. 1989;320:915-924.
12. Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med. 2000;28:1815-1826.
13. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest. 1999;103:1597-1604.
14. George J, Afek A, Shaish A, Levkovitz H, Bloom N, Cyrus T, Zhao L, Funk CD, Sigal E, Harats D. 12/15-lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation. 2001;104:1646-1650.
15. Harats D, Shaish A, George J, Mulkins M, Kurihara H, Levkovitz H, Sigal E. Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2000;20:2100-2105.
16. Shen J, Henderick E, Cornhill JF, Zsigmond E, Kim HS, Kuhn H, Guevara NV, Chan L. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest. 1996;98:2201-2208.
17. Trebus F, Heydeck D, Schimke I, Gerth C, Kühn H. Transient experimental anemia in cholesterol-fed rabbits induces systemic overexpression of the reticulocyte-type 15-lipoxygenase and protects from aortic lipid deposition. Prostaglandins Leukot Essent Fatty Acids. 2002;67:419-428.
18. Wissler RW. Update on the pathogenesis of atherosclerosis. Am J Med. 1991;91:3S-9S.
19. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
20. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
21. Gillmor SA, Villasenor A, Fletterick R, Sigal E, Browner MF. The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity. Nature Struct Biol. 1997;4:1003-1009.
22. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, Israel E, Schork N, Silverman ES, Katz DA, Drajesk J. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999;22:168-170.